Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Dexycu in Cataract Surgery
NCT02547623Phase 3Completed
- Sponsor
- Icon Bioscience, Inc.
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of IBI-10090 in post-operative inflammation, sponsored by Icon Bioscience, Inc.. Started Nov 2015; status: completed.
02
Drugs
IBI-10090
03
Conditions
post-operative inflammation
Beyond the preview
Go deeper on NCT02547623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547623.